Lead Sponsor

Guerbet

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Subject presenting with liver cirrhosis or chronic liver disease as shown by previous liver biopsy or by combination of clinical, endoscopic, biological, ultrasound parameters, and elastography
•Subject presenting with 1 to a maximum of 3 untreated hepatic nodule(s) of less than or equal to 3 cm (long axis) previously identified and/or characterized through enhanced CT and/or MRI within a maximum of 21 days before P03277 imaging, confirmed for HCC or not

•Subject presenting with hepatic nodule more than 3 cm in addition to nodule(s) less than or equal to 3 cm
•Subject already treated for HCC by surgery or thermal ablation for which the resection or coagulation area is less than 2 cm from the new nodule(s)
•Subject previously treated by transarterial chemoembolization
•Subject with moderate or severe renal impairment (eGFR \< 60 mL/min/1.73 m2) based on measurement done or available within the 7 days before P03277 administration and assessed after any iodinated contrast agent administration, or with dialysis end stage renal disease (ESRD)

Related studies

NCT06902246 · Unresectable Hepatocellular Carcinoma, Hepatocellular Carcinoma

NCT07422753 · Hepatocellular Carcinoma (HCC)

NCT07175441 · Advanced Unresectable Hepatocellular Carcinoma

NCT05969860 · Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma, and more

NCT06427941 · Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, and more

Proof of Concept Study Concerning Efficacy of P03277 MR Imaging in HCC Diagnosis